Bavelloni, Alberto, et al. “PI3Kα-Selective Inhibitor Alpelisib (BYL719), May Be Effective As Anticancer Agents in Rhabdomyosarcoma”. Italian Journal of Anatomy and Embryology, vol. 122, no. 1, Oct. 2017, p. 21, doi:10.36253/ijae-1730.